Cloudbreak Pharma Inc. (HKG:2592)

Market Cap	1.09B
Revenue (ttm)	1.97M -97.5%
Net Income	-526.63M
EPS	-0.80
Shares Out	844.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,150,000
Open	1.270
Previous Close	1.290
Day's Range	1.120 - 1.340
52-Week Range	1.200 - 9.740
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 5, 2026

About Cloudbreak Pharma

Cloudbreak Pharma Inc., a clinical-stage ophthalmology biotechnology company, researches and develops ophthalmic drugs for chronic eye diseases. The company develops CBT-001, which is in Phase 3 clinical trial for treating pterygium; CBT-009, a topical formulation of atropine that is in Phase 1/2 study indicated for the treatment of juvenile myopia; CBT-004, a VEGF receptor inhibitor, which is in Phase 2 clinical trial for treating vascularised pinguecula; and CBT-006, a cholesterol dissolving molecule containing the active pharmaceutical ingre...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 61
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2592

Financial Performance

In 2025, Cloudbreak Pharma's revenue was $253,000, a decrease of -97.52% compared to the previous year's $10.21 million. Losses were -$67.66 million, -31.75% less than in 2024.

Financial numbers in USD